621 related articles for article (PubMed ID: 26223157)
21. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
[TBL] [Abstract][Full Text] [Related]
22. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
24. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
25. Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.
Muramatsu H; Sakaguchi H; Taga T; Tabuchi K; Adachi S; Inoue M; Kitoh T; Suminoe A; Yabe H; Azuma E; Shioda Y; Ogawa A; Kinoshita A; Kigasawa H; Osugi Y; Koike K; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2014 May; 61(5):925-7. PubMed ID: 24302531
[TBL] [Abstract][Full Text] [Related]
26. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
27. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.
Holtick U; Shimabukuro-Vornhagen A; Chakupurakal G; Theurich S; Leitzke S; Burst A; Hallek M; von Bergwelt-Baildon M; Scheid C; Chemnitz JM
Eur J Haematol; 2016 May; 96(5):475-82. PubMed ID: 26132980
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission.
Fagioli F; Zecca M; Locatelli F; Lanino E; Uderzo C; Di Bartolomeo P; Berger M; Favre C; Rondelli R; Pession A; Messina C;
J Pediatr Hematol Oncol; 2008 Aug; 30(8):575-83. PubMed ID: 18799933
[TBL] [Abstract][Full Text] [Related]
29. Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia.
Molgaard-Hansen L; Möttönen M; Glosli H; Jónmundsson GK; Abrahamsson J; Hasle H;
Br J Haematol; 2011 Mar; 152(5):623-30. PubMed ID: 21241281
[TBL] [Abstract][Full Text] [Related]
30. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.
Hemmati PG; Terwey TH; Na IK; Jehn CF; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 Dec; 95(6):498-506. PubMed ID: 25598394
[TBL] [Abstract][Full Text] [Related]
33. Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Schmid C; Schleuning M; Tischer J; Holler E; Haude KH; Braess J; Haferlach C; Baurmann H; Oruzio D; Hahn J; Spiekermann K; Schlimok G; Schwerdtfeger R; Buechner T; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2012 Jan; 47(1):46-53. PubMed ID: 21358688
[TBL] [Abstract][Full Text] [Related]
34. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
35. The Cape Town experience with haematopoietic stem cell transplantation: the paediatric programme.
Roux P; Novitzky N
S Afr Med J; 2000 Aug; 90(8):804-11. PubMed ID: 11022631
[TBL] [Abstract][Full Text] [Related]
36. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
Novitzky N; Thomas V; du Toit C; McDonald A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
[TBL] [Abstract][Full Text] [Related]
38. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
40. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
